



Luxembourg, 05 December 2024

Environmental and Social Completion Sheet (ESCS)¹

Overview

Project Name: ORION - CORE THERAPEUTIC II
 Project Number: 2021-0183
 Country: Finland
 Project Description:

RDI investments in core therapeutic areas in 2021-2023.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The project included financing of the promoter's RDI activities which took place in the existing, already previously authorised, premises.

The promoter is committed to identifying impacts of and continued cooperation with its partners to ensure a sustainable supply chain. The promoter ensures compliance with Good Practices (GxP) and sustainable procurement standards, requiring suppliers to adhere to ethical business practices, labour standards, health and safety, and environmental management. Rigorous qualification processes, including audits and raw material testing, ensure supplier reliability. In its own operations, the promoter has implemented measures to enhance wastewater handling, improve occupational health and safety, and address key environmental aspects. The promoter aims to achieve carbon neutrality in its scope 1 and 2 emissions by 2030 and has committed to aligning its entire value chain with the 1.5°C global warming target, setting science-based emission reduction goals. Additionally, it is pursuing a 15% reduction in energy consumption by 2025, compared to 2016 levels, as part of its broader commitment to sustainability.

The project had a positive social impact. First, through support of a pharma company, highly skilled jobs are maintained in Finland and in Europe. Through this project, the development pipeline of the promoter was solidified and a new product was put on the market ensuring economic health of the promoter in the coming years. Secondly, the project contributes to the health of EU citizens, given that availability of medicines produced in Europe renders them accessible and less prone to geopolitical perturbations than medicines produced elsewhere.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the promoter that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.

¹ The template is for ILs and FLs